IP Library › Granted Patent US 12,195,552
Granted Patent B2
US 12,195,552 · App. 17/260,901 · Granted Jan 14, 2025

Linker for antibody-drug conjugates and its use

Inventors: Changjiang Huang (Yantai, CN); Hui Ye (Yantai, CN); Hu Chen (Yantai, CN); Xiuzhi Zhan (Yantai, CN); Nan Shen (Yantai, CN); Wenting Luo (Yantai, CN); Qiaohua Hou (Yantai, CN); Jianmin Fang (Yantai, CN)
Assignee: RemeGen Co., Ltd.
C07K16/32A61K45/06A61K47/545A61K47/68031A61K47/68033A61K47/6849A61K47/6851
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,552
App. No.
17/260,901
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable.

Claims (1)

1. A linker having the structure:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: HUANG, CHANGJIANG; YE, HUI; CHEN, HU; ZHAN, XIUZHI; SHEN, NAN; LUO, WENTING; HOU, QIAOHUA; FANG, JIANMIN
To: REMEGEN CO., LTD.
Reel/Frame 055696/0639 →
Priority Claims (1)
CN 201811541356 · Dec 17, 2018 · national
Continuity (1)
Related Publication 20220072137A1 · Mar 10, 2022
References Cited (51)
US 20120190579A1 · Smith et al. · 2012 [cited by applicant]
US 20130197059A1 · Goodnow, Jr. et al. · 2013 [cited by applicant]
US 20130224228A1 · Jackson · 2013 [cited by examiner]
US 20160015832A1 · An · 2016 [cited by examiner]
CN 103933575A · 2014 [cited by applicant]
CN 105592859A · 2016 [cited by applicant]
CN 106267225A · 2017 [cited by applicant]
CN 107400072A · 2017 [cited by applicant]
CN 107652219A · 2018 [cited by applicant]
CN 107921030A · 2018 [cited by applicant]
JP S5293765A · 1977 [cited by applicant]
JP H09506650A · 1997 [cited by applicant]
JP 2013501764A · 2013 [cited by applicant]
JP 2016531094A · 2016 [cited by applicant]
JP 2018515610A · 2018 [cited by applicant]
JP 2018529646A · 2018 [cited by applicant]
RU 2624732C2 · 2017 [cited by applicant]
SU 520040A3 · 1976 [cited by applicant]
TW 201718025A · 2017 [cited by applicant]
WO WO9516738A1 · 1995 [cited by applicant]
WO WO2008034124A2 · 2008 [cited by applicant]
WO WO2008034124A3 · 2008 [cited by applicant]
WO WO2013085925A1 · 2013 [cited by applicant]
WO WO2013121175A1 · 2013 [cited by applicant]
WO WO2014114207A1 · 2014 [cited by applicant]
WO WO2014197871A2 · 2014 [cited by applicant]
WO WO2015004400A1 · 2015 [cited by applicant]
WO WO2015151081A2 · 2015 [cited by applicant]
WO WO2015151081A3 · 2015 [cited by applicant]
WO WO2016004048A2 · 2016 [cited by applicant]
WO WO2016004048A3 · 2016 [cited by applicant]
WO WO2016064749A2 · 2016 [cited by examiner]
WO WO2016192528A1 · 2016 [cited by applicant]
WO WO2017031034A2 · 2017 [cited by applicant]
WO WO2017046658A1 · 2017 [cited by applicant]
WO WO2018185131A2 · 2018 [cited by applicant]
WO WO2018185131A3 · 2018 [cited by applicant]
WO WO2019033773A1 · 2019 [cited by applicant]
Li et al., Tetrahedron Letters. 2016: 57: 2660-3 (Year: 2016). [cited by examiner]
Carey, FA. Organic Chemistry 6th Ed. McGraw Hill. 2006, chapter 1, p. 9 (Year: 2006). [cited by examiner]
Japanese Office Action for Application No. 2021-517698, mailed Jan. 31, 2023. [cited by applicant]
Schumacher et al., In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug Chem. Feb. 16, 2011;22(2):132-6. doi: 10.1021/bc1004685. Epub Jan. 27, 2011. [cited by applicant]
Schumacher et al., Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org Biomol Chem. Oct. 7, 2014;12(37):7261-9. doi: 10.1039/c4ob01550a. [cited by applicant]
Office Action for Taiwanese Application No. TW108146262, mailed Jan. 8, 2021. [cited by applicant]
International Search Report and Written Opinion for PCT/CN2019/124982, mailed Mar. 12, 2020. [cited by applicant]
Extended European Search Report for Application No. 19900942.4, mailed May 13, 2022. [cited by applicant]
Japanese Office Action for Application No. 2021-517698, mailed Jun. 21, 2022. [cited by applicant]
Li et al., A mild and selective protecting and reversed modification of thiols. Tetrahedron Letters. 2016; 57: 2660-3. [cited by applicant]
Ramesh et al., 6-(Bromomaleimido)hexanoic acid as a connector for the construction of multiple branched peptide platforms. Org Lett. Feb. 6, 2015;17(3):464-7. doi: 10.1021/01503463u. Epub Jan. 12, 2015. [cited by applicant]
Shen et al., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. Jan. 22, 2012;30(2):184-9. doi: 10.1038/nbt.2108. [cited by applicant]
International Preliminary Report on Patentability for PCT/CN2019/124982, mailed Jul. 1, 2021. [cited by applicant]